Clinical Cancer Research The Science of Cancer Health Disparities Stand Up to Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nitori, N.
Right arrow Articles by Hirohashi, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nitori, N.
Right arrow Articles by Hirohashi, S.
Clinical Cancer Research Vol. 11, 2531-2539, April 2005
© 2005 American Association for Cancer Research


Imaging, Diagnosis, Prognosis

Prognostic Significance of Tissue Factor in Pancreatic Ductal Adenocarcinoma

Nobuhiro Nitori1,5, Yoshinori Ino1, Yukihiro Nakanishi1, Tesshi Yamada2, Kazufumi Honda2, Kazuyoshi Yanagihara3, Tomoo Kosuge4, Yae Kanai1, Masaki Kitajima5 and Setsuo Hirohashi1

Authors' Affiliations: 1 Pathology, 2 Chemotherapy Divisions, and 3 Central Animal Laboratory, National Cancer Center Research Institute, 4 Department of Surgery, National Cancer Center Hospital, and 5 Department of Surgery, Keio University School of Medicine, Tokyo, Japan

Tissue factor (TF) is a transmembrane glycoprotein that plays roles in the blood coagulation and intracellular signaling pathways, and has also been suggested to modulate the biological behavior of cancer cells. In order to examine the clinicopathologic significance of TF expression in pancreatic ductal adenocarcinoma, TF expression was determined by immunohistochemistry using a newly raised anti-TF monoclonal antibody in 113 patients who had undergone surgical resection of pancreatic ductal adenocarcinoma. According to the incidence of tumor cell immunopositivity, patients were divided into "negative TF" (0%), "weak TF" (<25%), or "high TF" (25% or more) groups, which accounted for 11.6% (n = 13), 44.2% (n = 50), and 44.2% (n = 50) of the total, respectively. Increased TF expression was correlated with the extent of the primary tumor (P = 0.0043), lymph node metastasis (P = 0.0043), lymphatic distant metastasis (P = 0.0039), advanced tumor-node-metastasis stage (P = 0.0002), and high tumor grade (P = 0.0164). Multivariate analysis using the Cox proportional hazards model showed that high TF expression was an independent negative predictor for survival (hazard ratio, 2.014; P = 0.0076). Moreover, patients with TF-negative tumors had a significantly better prognosis even if lymph node metastasis was present (P < 0.0001). We also showed that TF knockdown by RNA interference suppressed the invasiveness of a pancreatic adenocarcinoma cell line in vitro. These results indicate that TF expression may contribute to the aggressiveness of pancreatic ductal adenocarcinoma by stimulating tumor invasiveness, and that evaluation of the primary tumor for TF expression may identify patients with a poor prognosis.

Key Words: Tissue factor • pancreatic cancer • immunohistochemistry • invasion • metastasis




This article has been cited by other articles:


Home page
Cancer Res.Home page
J. P. Venables, R. Klinck, A. Bramard, L. Inkel, G. Dufresne-Martin, C. Koh, J. Gervais-Bird, E. Lapointe, U. Froehlich, M. Durand, et al.
Identification of Alternative Splicing Markers for Breast Cancer
Cancer Res., November 15, 2008; 68(22): 9525 - 9531.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
M. Mandala, M. Reni, S. Cascinu, S. Barni, I. Floriani, S. Cereda, R. Berardi, S. Mosconi, V. Torri, and R. Labianca
Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients
Ann. Onc., October 1, 2007; 18(10): 1660 - 1665.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. A. Khorana, S. A. Ahrendt, C. K. Ryan, C. W. Francis, R. H. Hruban, Y. C. Hu, G. Hostetter, J. Harvey, and M. B. Taubman
Tissue Factor Expression, Angiogenesis, and Thrombosis in Pancreatic Cancer
Clin. Cancer Res., May 15, 2007; 13(10): 2870 - 2875.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
E. Giovannetti, V. Mey, S. Nannizzi, G. Pasqualetti, M. Del Tacca, and R. Danesi
Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer.
Mol. Cancer Ther., June 1, 2006; 5(6): 1387 - 1395.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
L. Y. Han, C. N. Landen Jr, A. A. Kamat, A. Lopez, D. P. Bender, P. Mueller, R. Schmandt, D. M. Gershenson, and A. K. Sood
Preoperative Serum Tissue Factor Levels Are an Independent Prognostic Factor in Patients With Ovarian Carcinoma
J. Clin. Oncol., February 10, 2006; 24(5): 755 - 761.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Hayashida, K. Honda, M. Idogawa, Y. Ino, M. Ono, A. Tsuchida, T. Aoki, S. Hirohashi, and T. Yamada
E-Cadherin Regulates the Association between {beta}-Catenin and Actinin-4
Cancer Res., October 1, 2005; 65(19): 8836 - 8845.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.